来那度胺治疗5号染色体长臂31区缺失（del(5)(q31)）相关的骨髓纤维化：细胞遗传学和JAK2V617F分子缓解 - Suppr

Suppr

超能文献

Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions.

作者信息

Tefferi A, Lasho T L, Mesa R A, Pardanani A, Ketterling R P, Hanson C A

出版信息

Leukemia. 2007 Aug;21(8):1827-8. doi: 10.1038/sj.leu.2404711. Epub 2007 Apr 26.

DOI:10.1038/sj.leu.2404711

PMID:17460705

Abstract

摘要

相似文献

Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions.来那度胺治疗5号染色体长臂31区缺失（del(5)(q31)）相关的骨髓纤维化：细胞遗传学和JAK2V617F分子缓解

Leukemia. 2007 Aug;21(8):1827-8. doi: 10.1038/sj.leu.2404711. Epub 2007 Apr 26.

Treatment of deletion 5q acute myeloid leukemia with lenalidomide.来那度胺治疗5q缺失急性髓系白血病

Leukemia. 2007 Mar;21(3):586-8. doi: 10.1038/sj.leu.2404526. Epub 2007 Jan 18.

Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation.来那度胺治疗伴有孤立性5号染色体长臂缺失（del(5q)）和JAK2 V617F突变的骨髓增生异常综合征患者的疗效

Leuk Res. 2011 Sep;35(9):1276-8. doi: 10.1016/j.leukres.2011.06.008. Epub 2011 Jul 20.

Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome.来那度胺单药治疗JAK2（V617F）阳性、del（5）（q13q33）骨髓增生异常综合征所致急性髓系白血病的血液学和细胞遗传学反应

Leukemia. 2006 Nov;20(11):2063-4. doi: 10.1038/sj.leu.2404398. Epub 2006 Sep 21.

Thalidomide and lenalidomide in primary myelofibrosis.沙利度胺和来那度胺治疗原发性骨髓纤维化

Neth J Med. 2010 Aug;68(1):293-8.

Haematological and cytogenetic responses after only 7 days of Lenalidomide in a patient with myelodysplastic syndrome and chromosome 5q deletion.来那度胺治疗仅7天后，一名患有骨髓增生异常综合征且5号染色体长臂缺失患者的血液学和细胞遗传学反应。

Leuk Res. 2011 Sep;35(9):e175-6. doi: 10.1016/j.leukres.2011.05.020. Epub 2011 Jun 11.

Response to lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2 V617F mutation.来那度胺对一名伴有孤立性5号染色体长臂缺失（del(5q)）和JAK2 V617F突变的骨髓增生异常综合征患者的疗效。

Leuk Lymphoma. 2010 Oct;51(10):1941-3. doi: 10.3109/10428194.2010.506567.

Sudden acute leukemia transformation in a MDS patient with del(5q) in complete cytogenetic remission after lenalidomide.来那度胺治疗后细胞遗传学完全缓解的伴有del(5q)的骨髓增生异常综合征患者发生急性白血病急变。

Leuk Res. 2011 Jun;35(6):e69-70. doi: 10.1016/j.leukres.2010.12.019. Epub 2011 Jan 12.

Efficacy of lenalidomide treatment and complete cytogenetic remission in a case of myelodysplastic syndrome with del(5q) and del(9q).来那度胺治疗伴有del(5q)和del(9q)的骨髓增生异常综合征患者的疗效及细胞遗传学完全缓解情况

Leuk Res. 2010 Jul;34(7):e169-72. doi: 10.1016/j.leukres.2009.12.015. Epub 2010 Jan 31.

A delayed yet durable response to very short lenalidomide therapy and unexpected clone redistribution in a case of myelodysplastic syndrome with del(5q) and del(20q).一例伴有5号染色体长臂缺失（del(5q)）和20号染色体长臂缺失（del(20q)）的骨髓增生异常综合征患者对极短疗程来那度胺治疗的延迟但持久的反应及意外的克隆重新分布

Leuk Res. 2009 Nov;33(11):e199-202. doi: 10.1016/j.leukres.2009.06.009. Epub 2009 Jul 9.

引用本文的文献

Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis.莫米松（JAK1/JAK2/ACVR1 抑制剂）：作用机制、临床试验报告以及除骨髓纤维化之外的治疗前景。

Haematologica. 2023 Nov 1;108(11):2919-2932. doi: 10.3324/haematol.2022.282612.

Myelofibrosis.骨髓纤维化。

Blood. 2023 Apr 20;141(16):1954-1970. doi: 10.1182/blood.2022017423.

Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape.骨髓纤维化：遗传特征与新兴治疗领域。

Cancer Res. 2022 Mar 1;82(5):749-763. doi: 10.1158/0008-5472.CAN-21-2930.

Treatment of MDS/MPN and the MDS/MPN IWG International Trial: ABNL MARRO.MDS/MPN 治疗和 MDS/MPN IWG 国际试验：ABNL MARRO。

Curr Hematol Malig Rep. 2019 Dec;14(6):543-549. doi: 10.1007/s11899-019-00553-5.

Guideline on myeloproliferative neoplasms: Associacão Brasileira de Hematologia, Hemoterapia e Terapia Cellular: Project guidelines: Associação Médica Brasileira - 2019.骨髓增殖性肿瘤指南：巴西血液学、血液治疗与细胞治疗协会：项目指南：巴西医学协会 - 2019年

Hematol Transfus Cell Ther. 2019 Jul;41 Suppl 1(Suppl 1):1-73. doi: 10.1016/j.htct.2019.03.001. Epub 2019 May 10.

Management of Myelofibrosis-Related Cytopenias.骨髓纤维化相关血细胞减少症的治疗管理。

Curr Hematol Malig Rep. 2018 Jun;13(3):164-172. doi: 10.1007/s11899-018-0447-9.

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.费城染色体阴性经典骨髓增殖性肿瘤：欧洲白血病网的修订管理建议。

Leukemia. 2018 May;32(5):1057-1069. doi: 10.1038/s41375-018-0077-1. Epub 2018 Feb 27.

Pharmacotherapy of Myelofibrosis.骨髓纤维化的药物治疗。

Drugs. 2017 Sep;77(14):1549-1563. doi: 10.1007/s40265-017-0797-y.

Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.骨髓增殖性肿瘤 2.2017 年版，NCCN 肿瘤临床实践指南。

J Natl Compr Canc Netw. 2016 Dec;14(12):1572-1611. doi: 10.6004/jnccn.2016.0169.

Myelofibrosis: an update on drug therapy in 2016.骨髓纤维化：2016年药物治疗最新进展

Expert Opin Pharmacother. 2016 Dec;17(18):2375-2389. doi: 10.1080/14656566.2016.1252333. Epub 2016 Nov 7.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验